Indivior appoints Patrick Barry as Chief Commercial Officer

RICHMOND, Va. - Indivior PLC (NASDAQ:LSE: INDV), a global pharmaceutical company with a market capitalization of $1.46 billion and impressive gross profit margins of 81.6%, has announced the appointment of Patrick Barry as its new Chief Commercial Officer, effective June 2. Barry will be responsible for leading Indivior’s commercial growth strategy and operations, with a focus on the company’s efforts to combat opioid use disorder, primarily through its product SUBLOCADE® (buprenorphine extended-release) Injection. According to InvestingPro data, the company generated $1.17 billion in revenue over the last twelve months.

Barry, with over 30 years of experience in the pharmaceutical sector, joins Indivior’s executive committee bringing a history of commercial leadership and a proven track record of driving revenue growth. His previous role was as executive vice president and chief commercial officer at Endo Pharmaceuticals, where he managed commercial activities that generated approximately $2 billion in revenue.

Joe Ciaffoni, CEO of Indivior, expressed confidence in Barry’s capabilities, citing his extensive experience and successful track record in branded medicines as assets that will contribute to the company’s growth potential.

Indivior’s mission is to transform the treatment of opioid use disorder into a manageable chronic disease, providing accessible, evidence-based treatments globally. The company, headquartered in Richmond, Virginia, operates in over 30 countries and is committed to expanding its product portfolio to address opioid use disorder.

Barry’s appointment comes at a time when Indivior is poised to strengthen its market position in opioid use disorder treatments. Barry himself expressed honor in joining Indivior and a commitment to growing the SUBLOCADE brand and maximizing the potential of Indivior’s portfolio.

This strategic executive appointment is based on Indivior’s press release statement and aims to further the company’s impact in the pharmaceutical industry, particularly in the area of opioid use disorder treatments.

In other recent news, Indivior PLC has announced several significant developments following its Annual General Meeting (AGM). The company reported the departure of CEO Mark Crossley, with Joe Ciaffoni stepping in as the new CEO. Shareholders approved changes to the company’s articles of association, reflecting its transition from the London Stock Exchange to the Nasdaq Stock Market. Additionally, all proposed resolutions were passed, including the reappointment of PricewaterhouseCoopers LLP as the auditor. The company also addressed the remuneration policy in communications with shareholders, emphasizing clarity on this key agenda item. Indivior plans to streamline its Board of Directors to seven members, with all directors standing for re-election at the 2025 AGM. The board will see further changes, with new appointments and the stepping down of some directors. These governance adjustments are part of a revised agreement with major shareholder Oaktree Capital Management. Indivior continues to focus on its mission of addressing addiction treatment challenges.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.